Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda and Kyoto University to ally on drug research

Takeda and Kyoto University to ally on drug research

18th January 2011

Takeda has formed a research and development alliance with Kyoto University that will see the two organisations working to discover new treatments for obesity and schizophrenia.

Under the terms of the five-year partnership, the bodies will be aiming to identify drug targets and biomarkers that will assist in the development of CNS-acting compounds for these two conditions.

Research will be taking place at the university's Medical Innovation Center, an open innovation laboratory specifically designed for use in collaborative projects between the industry, academia and Japan's government.

Takeda will also be using its worldwide networks to provide information and clinical data that can assist in medical research into its new drug candidates.

Dr Shigenori Ohkawa, executive vice-president and chief scientific officer of Takeda, said: "Through the close partnership on research and development, we expect that we will be able to create innovative drugs for obesity and schizophrenia where there is a high unmet need for patients."

Earlier this month, the firm licensed a new biomarker from Zinfandel Pharmaceuticals that may be useful in assessing patients' risk of Alzheimer's disease.ADNFCR-8000103-ID-800348158-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.